The proteomics market size was exhibited at USD 27.95 billion in 2024 and is projected to hit around USD 95.81 billion by 2034, growing at a CAGR of 13.11% during the forecast period 2024 to 2034.
The rising prevalence of chronic & infectious diseases, the increasing demand for rapid & advanced diagnostic solutions in target disease treatment, and the growing demand for personalized medicine are some of the factors contributing to market growth. Moreover, technological advancements in protein analysis further propel the growth.
The U.S. proteomics market size is evaluated at USD 10.5 billion in 2024 and is projected to be worth around USD 32.32 billion by 2034, growing at a CAGR of 11.9% from 2024 to 2034.
North America dominated the market and accounted for 46.0% revenue share in 2024 owing to the advancements in technology and growing demand for advanced disease diagnostics. Furthermore, the region benefits from substantial research and development investments in precision medicine, government funding for biotechnology and healthcare research, and highly advanced healthcare infrastructure.
U.S. Proteomics Market Trends
The proteomics market in the U.S. is expected to grow over the forecast period due to the robust research and development landscape in biotechnology and life sciences, harnessing innovation & technological advancements in mass spectrometry and its application in medicine and biotechnology research, and the presence of key players in the country.
Europe Proteomics Market Trends
The European proteomics market is expected to grow at a significant CAGR from 2024 to 2034, owing to the established biotechnology research and development sector, growing focus on spatial biology research, and the presence of key players. Furthermore, significant investments and funding from public and private sources enable the expansion of proteomics research and the commercialization of proteomics products.
The proteomics market in the UK is expected to grow over the forecast period, driven by technological advancements in mass spectrometry and its increasing applications in various fields, such as oncology, neurology, immunology, pathology, and personalized medicine.
Germany's proteomics market is witnessing substantial growth in the multi-omics field. It is characterized by active participation from renowned academic institutions, biotechnology and pharmaceutical companies, and government funding for research projects. For instance, in February-March 2024, the European Molecular Biology Laboratory (EMBL) in Germany hosted a series of events and courses with a primary focus on integrating and analyzing multiomics data.
The proteomics market in France is predicted to witness significant growth due to the increasing adoption of advanced protein analysis technologies and the expanding applications in various fields, including cancer research, drug discovery, and translational research. In addition, government initiatives and investments in proteomics research further support the market's growth in France.
Asia Pacific Proteomics Market Trends
Asia Pacific proteomics marketis anticipated to witness the fastest CAGR of 15.97% from 2024 to 2034 due to the rising prevalence of chronic diseases, rising preference for outsourcing proteomics-based projects, public and private funding for research and development for proteomics studies, favorable government regulations, and a strong presence of biotechnology and biopharmaceutical companies in the region.
The Japan proteomics market is anticipated to grow at a significant CAGR over the forecast period. Robust investments in drug discovery & development, increasing preference for personalized medicine, technological advancements, and supportive government policies are some of the factors contributing to market growth.
The proteomics market in China is expected to grow over the forecast period owing to the increasing investments in healthcare innovation and research. The country’s focus on advancing biotechnology and therapeutics, coupled with the rising awareness of precision and medicine, is driving the market expansion. Moreover, with the increasing prevalence of chronic diseases, there is a growing demand for effective diagnostic tools, further fueling market growth.
The proteomics market in India is anticipated to grow rapidly over the forecast period due to the increasing use of proteomics-based research and the presence of biopharmaceutical companies involved in drug discovery and development. Moreover, the rise of government investment in research activities further boosts market growth.
Middle East and Africa Proteomics Market Trends
The proteomics market in the Middle East and Africais expected to exhibit growth in the near future due to a rise in the demand for improved diagnostics that aid in the prevention & treatment of diseases, along with increasing government funding in biotechnology research.
The proteomics market in Saudi Arabia is expected to grow over the forecast period due to substantial investment in biotechnology, increased research activities, and government initiatives supporting scientific advancements.
The Kuwait proteomics market is anticipated to witness growth over the forecast period. Kuwaiti institutions are engaging with global researchers and biotech companies to advance biotechnology research. These partnerships enhance the exchange of knowledge and access to advanced technologies, which can boost the market in the country.
Report Coverage | Details |
Market Size in 2025 | USD 31.61 Billion |
Market Size by 2034 | USD 95.81 Billion |
Growth Rate From 2024 to 2034 | CAGR of 13.11% |
Base Year | 2024 |
Forecast Period | 2024-2034 |
Segments Covered | Product & Services, Application, Technology, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
Key Companies Profiled | Illumina, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Bruker Corporation; F. Hoffmann-La Roche Ltd.; Waters Corporation; Merck KGaA; Danaher; Standard BioTools Inc. |
The reagents & consumables segment accounted for the largest revenue share of 72.29% in 2024. Kits designed for mass spectrometry enable researchers to identify proteins within complex biological samples accurately. They facilitate the quantification of protein levels, which is essential for understanding cellular functions and disease mechanisms. Reagents for proteomic assays help identify novel biomarkers critical for early disease diagnosis, particularly in conditions like cancer, Alzheimer’s, and cardiovascular diseases. This leads to the development of targeted therapies.
The services segment is projected to grow at the fastest CAGR from 2024 to 2034 due to the increasing demand for specialized expertise and advanced technologies in protein analysis. As proteomics research becomes more complex, many organizations outsource tasks like mass spectrometry, protein identification, and data analysis to specialized service providers such as Charles River Laboratories, Cell Signaling Technology, Creative Proteomics, and others. These providers offer cutting-edge technology, comprehensive data interpretation, and cost-effective solutions, enabling researchers to focus on core activities. Furthermore, the rising adoption of personalized medicine and biomarker discovery drives the need for high-quality proteomic services, further accelerating the growth of this segment.
The spectrometry segment captured the largest revenue share in 2024. It is also expected to expand further at the highest CAGR of 14.77% during the forecast period. Spectrometry technology is used for identification and characterization of proteins, detection of post-translational modifications, and analysis of protein-protein interactions in proteomics studies. Advancements in mass spectrometry technology, such as increased resolution, speed, and automation, have significantly enhanced its efficiency, making it a preferred tool for proteomics research. Furthermore, the integration of spectrometry techniques with bioinformatics for data analysis has expanded its applications in drug discovery, biomarker identification, and personalized medicine. These factors are anticipated to drive the segment over the forecast period.
The next-generation sequencing (NGS) segment is projected to grow at a significant pace from 2024 to 2034. The declining costs of sequencing technologies have made NGS more accessible to a wider range of research and clinical applications. This cost reduction, coupled with technological advancements that have increased speed and accuracy, is driving broader adoption in various fields, including oncology, genetic disease research, and personalized medicine. Companies involved in the market are tapping into this increasing demand by undertaking various strategic initiatives. For instance, in February 2024, Pixelgen Technologies signed a non-exclusive agreement with Japan's BioStream Co. Ltd to distribute its innovative next generation sequencing spatial proteomics tools for single cells. Such initiatives are likely to boost the growth of the segment.
The drug discovery segment dominated the proteomics market with the largest revenue share of 53.0% in 2024. This large share can be attributed to the development of structure-based drug design, a greater emphasis on creating personalized drugs, and increased investments in these areas. Additionally, proteomics technologies provide an early indication of a drug's potential in the discovery process, leading to significant cost savings for pharmaceutical companies and ultimately benefiting patients and healthcare systems, thus contributing to the segment's growth.
The clinical diagnostics segment is expected to experience the fastest CAGR during the forecast period. This is attributed to the high adoption of protein analysis among clinical researchers to identify biomarkers for early disease detection and identifying individual risk factors. This is expected to create new opportunities for prevention and early intervention of the disease. With the help of proteomics-based diagnosis, it is possible to uncover potential biomarkers and protein expression patterns that can be used to classify and predict tumors, and determine their prognosis, which further contributes to the segment’s growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the proteomics market
By Product & Services
By Application
By Technology
By Regional
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product & Service Segment
1.2.2. Application Segment
1.2.3. Technology Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Proteomics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising prevalence of chronic and infectious diseases
3.2.1.2. Growing preference for personalized medicine
3.2.1.3. Technological advancements in proteomics techniques
3.2.2. Market restraint analysis
3.2.2.1. High cost of proteomics tools and instruments
3.3. Proteomics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Proteomics Market: Product & Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Proteomics Market Product & Service Movement Analysis
4.3. Global Proteomics Market Size & Trend Analysis, by Product & Service, 2021 to 2034 (USD Million)
4.4. Instruments
4.4.1. Instruments market estimates and forecasts 2021 to 2034 (USD Million)
4.5. Reagents & Consumables
4.5.1. Reagents & consumables market estimates and forecasts 2021 to 2034 (USD Million)
4.6. Services
4.6.1. Services market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 5. Proteomics Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Proteomics Market Application Movement Analysis
5.3. Global Proteomics Market Size & Trend Analysis, by Application, 2021 to 2034 (USD Million)
5.4. Drug Discovery
5.4.1. Drug discovery market estimates and forecasts 2021 to 2034 (USD Million)
5.5. Clinical Diagnostics
5.5.1. Clinical diagnostics market estimates and forecasts 2021 to 2034 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 6. Proteomics Market: Technology Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Proteomics Market Technology Movement Analysis
6.3. Global Proteomics Market Size & Trend Analysis, by Technology, 2021 to 2034 (USD Million)
6.4. Next-generation Sequencing
6.4.1. Next-generation sequencing market estimates and forecasts 2021 to 2034 (USD Million)
6.5. Microarray Instruments
6.5.1. Microarray instruments market estimates and forecasts 2021 to 2034 (USD Million)
6.6. X-ray Crystallography
6.6.1. X-ray crystallography market estimates and forecasts 2021 to 2034 (USD Million)
6.7. Spectrometry
6.7.1. Spectrometry market estimates and forecasts 2021 to 2034 (USD Million)
6.8. Chromatography
6.8.1. Chromatography market estimates and forecasts 2021 to 2034 (USD Million)
6.9. Protein Fractionation Systems
6.9.1. Protein fractionation systems market estimates and forecasts 2021 to 2034 (USD Million)
6.10. Electrophoresis
6.10.1. Electrophoresis market estimates and forecasts 2021 to 2034 (USD Million)
6.11. Surface Plasma Resonance (SPR) Systems
6.11.1. Surface plasma resonance (SPR) systems market estimates and forecasts 2021 to 2034 (USD Million)
6.12. Other Technologies
6.12.1. Other technologies market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 7. Proteomics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2034:
7.4. North America
7.4.1. North America market estimates and forecasts 2021 to 2034 (USD Million)
7.4.2. U.S.
7.4.2.1. Key country dynamics
7.4.2.2. Competitive scenario
7.4.2.3. Regulatory framework
7.4.2.4. U.S. market estimates and forecasts 2021 to 2034 (USD Million)
7.4.3. Canada
7.4.3.1. Key country dynamics
7.4.3.2. Competitive scenario
7.4.3.3. Regulatory framework
7.4.3.4. Canada market estimates and forecasts 2021 to 2034 (USD Million)
7.4.4. Mexico
7.4.4.1. Key country dynamics
7.4.4.2. Competitive scenario
7.4.4.3. Regulatory framework
7.4.4.4. Mexico market estimates and forecasts 2021 to 2034 (USD Million)
7.5. Europe
7.5.1. Europe market estimates and forecasts 2021 to 2034 (USD Million)
7.5.2. UK
7.5.2.1. Key country dynamics
7.5.2.2. Competitive scenario
7.5.2.3. Regulatory framework
7.5.2.4. UK market estimates and forecasts 2021 to 2034 (USD Million)
7.5.3. Germany
7.5.3.1. Key country dynamics
7.5.3.2. Competitive scenario
7.5.3.3. Regulatory framework
7.5.3.4. Germany market estimates and forecasts 2021 to 2034 (USD Million)
7.5.4. France
7.5.4.1. Key country dynamics
7.5.4.2. Competitive scenario
7.5.4.3. Regulatory framework
7.5.4.4. France market estimates and forecasts 2021 to 2034 (USD Million)
7.5.5. Italy
7.5.5.1. Key country dynamics
7.5.5.2. Competitive scenario
7.5.5.3. Regulatory framework
7.5.5.4. Italy market estimates and forecasts 2021 to 2034 (USD Million)
7.5.6. Spain
7.5.6.1. Key country dynamics
7.5.6.2. Competitive scenario
7.5.6.3. Regulatory framework
7.5.6.4. Spain market estimates and forecasts 2021 to 2034 (USD Million)
7.5.7. Norway
7.5.7.1. Key country dynamics
7.5.7.2. Competitive scenario
7.5.7.3. Regulatory framework
7.5.7.4. Norway market estimates and forecasts 2021 to 2034 (USD Million)
7.5.8. Sweden
7.5.8.1. Key country dynamics
7.5.8.2. Competitive scenario
7.5.8.3. Regulatory framework
7.5.8.4. Sweden market estimates and forecasts 2021 to 2034 (USD Million)
7.5.9. Denmark
7.5.9.1. Key country dynamics
7.5.9.2. Competitive scenario
7.5.9.3. Regulatory framework
7.5.9.4. Denmark market estimates and forecasts 2021 to 2034 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific market estimates and forecasts 2021 to 2034 (USD Million)
7.6.2. Japan
7.6.2.1. Key country dynamics
7.6.2.2. Competitive scenario
7.6.2.3. Regulatory framework
7.6.2.4. Japan market estimates and forecasts 2021 to 2034 (USD Million)
7.6.3. China
7.6.3.1. Key country dynamics
7.6.3.2. Competitive scenario
7.6.3.3. Regulatory framework
7.6.3.4. China market estimates and forecasts 2021 to 2034 (USD Million)
7.6.4. India
7.6.4.1. Key country dynamics
7.6.4.2. Competitive scenario
7.6.4.3. Regulatory framework
7.6.4.4. India market estimates and forecasts 2021 to 2034 (USD Million)
7.6.5. Australia
7.6.5.1. Key country dynamics
7.6.5.2. Competitive scenario
7.6.5.3. Regulatory framework
7.6.5.4. Australia market estimates and forecasts 2021 to 2034 (USD Million)
7.6.6. South Korea
7.6.6.1. Key country dynamics
7.6.6.2. Competitive scenario
7.6.6.3. Regulatory framework
7.6.6.4. South Korea market estimates and forecasts 2021 to 2034 (USD Million)
7.6.7. Thailand
7.6.7.1. Key country dynamics
7.6.7.2. Competitive scenario
7.6.7.3. Regulatory framework
7.6.7.4. Thailand market estimates and forecasts 2021 to 2034 (USD Million)
7.7. Latin America
7.7.1. Latin America market estimates and forecasts 2021 to 2034 (USD Million)
7.7.2. Brazil
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. Brazil market estimates and forecasts 2021 to 2034 (USD Million)
7.7.3. Argentina
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Argentina market estimates and forecasts 2021 to 2034 (USD Million)
7.8. MEA
7.8.1. MEA market estimates and forecasts 2021 to 2034 (USD Million)
7.8.2. South Africa
7.8.2.1. Key country dynamics
7.8.2.2. Competitive scenario
7.8.2.3. Regulatory framework
7.8.2.4. South Africa market estimates and forecasts 2021 to 2034 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key country dynamics
7.8.3.2. Competitive scenario
7.8.3.3. Regulatory framework
7.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2034 (USD Million)
7.8.4. UAE
7.8.4.1. Key country dynamics
7.8.4.2. Competitive scenario
7.8.4.3. Regulatory framework
7.8.4.4. UAE market estimates and forecasts 2021 to 2034 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key country dynamics
7.8.5.2. Competitive scenario
7.8.5.3. Regulatory framework
7.8.5.4. Kuwait market estimates and forecasts 2021 to 2034 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Position Analysis, 2024
8.4. Company Profiles/Listing
8.4.1. Illumina Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product/Service benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Agilent Technologies Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/Service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Bio-Rad Laboratories, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/Service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Thermo Fisher Scientific, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/Service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Bruker Corporation
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/Service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. F. Hoffmann-La Roche Ltd.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/Service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Waters Corporation
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/Service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Merck KGaA
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/Service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Danaher
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/Service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Standard BioTools Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/Service benchmarking
8.4.10.4. Strategic initiatives